Table 2 Patient disposition

Patient number

165

127

38

Treatment duration (mo.), median (range)

30.7 (1.2–58.6)

34.5 (1.2–57.5)

25.5 (1.4–58.6)

Ongoing, n (%)

114 (69.1)

96 (75.6)

18 (47.4)

Olverembatinib 20 mg

11 (9.6)

8 (8.3)

3 (16.7)

Olverembatinib 30 mg

44 (38.6)

38 (39.6)

6 (33.3)

Olverembatinib 40 mg

48 (42.1)

41 (42.7)

7 (38.9)

Olverembatinib 50 mg

11 (9.6)

9 (9.4)

2 (11.1)

Discontinuation, n (%)

51 (30.9)

31 (24.4)

20 (52.6)

Disease progression

15 (9.1)

5 (3.9)

10 (26.3)

Adverse events

13 (7.9)

9 (7.1)

4 (10.5)

Treatment failure

12 (7.2)

8 (6.3)

4 (10.5)

Withdrawal by subject

8 (4.8)

8 (6.3)

0

Death

3 (1.8)

1 (0.8)

2 (5.3)